Early Outcomes of Intravitreal Aflibercept 8 mg in Eyes Previously Treated with Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration with AI-Based Biomarker Quantification

Key Points

• To evaluate the short-term anatomical and durability outcomes of intravitreal aflibercept 8 mg in eyes previously treated with aflibercept 2 mg for neovascular age-related macular degeneration (nAMD).
• Conducted a real-world study on patients treated with intravitreal afl8.
• Evaluated anatomical and durability outcomes post-treatment.
• Utilized AI-based biomarker quantification for data analysis.
• Noted potential short-term benefits of afl8 in enhancing anatomical outcomes.
• Demonstrated improved durability in treated eyes.
• Highlighted added value from data-driven evaluations.